GALMED PHARMACEUTICALS LTD (GLMD) Stock News

USA - NASDAQ:GLMD - IL0011313900 - Common Stock

1.16 USD

-0.07 (-5.69%)

Last: 11/7/2025, 12:08:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GLMD Latest News, Press Relases and Analysis

All

Press Releases

25 days ago - By: Benzinga - Mentions: PTIX CASI TLPH NDRA ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: Benzinga - Mentions: SNWV ONMD APVO PCSA ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

2 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value

a year ago - By: InvestorPlace

GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024

6 months ago - By: Stocktwits

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’

6 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

6 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

7 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

7 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

7 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

7 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

8 months ago - By: Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

a year ago - By: Galmed Pharmaceuticals Ltd.

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

a year ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA NVS MRK ...

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs